MedTrace Logo

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

NCT02079168 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2016-06-14

No results posted yet for this study

Summary

To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.

Conditions

  • Keloid

Interventions

DRUG

RXI-109

DRUG

Placebo

Sponsors & Collaborators

  • RXi Pharmaceuticals, Corp.

    lead INDUSTRY

Principal Investigators

  • Pamela Pavco, PhD · RXi Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States
  • Dominican Republic

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02079168 on ClinicalTrials.gov